Page results
-
UCLH is managing one of the three cancer hubs across London, so that during the COVID-19 coronavirus pandemic cancer surgery is available for patients with the most immediate needs.
-
One of our patients who is recovering from COVID-19 has been appearing across national media as she recounts her story and thanks the staff who saved her life.
-
This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.
-
The National Day Care Unit provides an opportunity for many people to receive different treatments, tests and procedures without having to stay overnight in the hospital. Some eligible patients who need more than one day of treatment will stay in a hotel near to the hospital.
-
UCLH has continued to achieve excellent results in the National Inpatient Survey, with patients rating their overall care as 8.7 out of 10 – the top score amongst our London peers.
-
John McGrath is a newly appointed governor as a stakeholder member from North Central London Clinical Commissioning Group (CCG). He is a local GP and has lived and worked in Islington for the last decade in a number of different settings, including multiple GP surgeries as a salaried doctor, local A&E departments and urgent care.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
This page has been written by the Spasticity Team at the National Hospital for Neurology and Neurosurgery for patients (or their family or carers) who have been referred to our service or are under the care of the team at this hospital.
-
The special haematology service provides a comprehensive investigation of haemolytic amaemia, haemoglobinopathies and red cell enzymopathy.
File results
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0235 - Hip and knee arthroplasty litigation
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0215 - British sign language procurement and communications